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MaOBJECTIVES This study investigated the feasibility of visual and quantitative assessment of coronary vessel wall
contrast enhancement (CE) for detection of symptomatic atherosclerotic coronary artery disease (CAD) and subclinical
coronary vasculitis in autoimmune inflammatory disease (systemic lupus erythematosus [SLE]), as well as the association
with aortic stiffness, an established marker of risk.
BACKGROUND Coronary CE by cardiac magnetic resonance (CMR) is a novel noninvasive approach to visualize
gadolinium contrast uptake within the coronary artery vessel wall.
METHODS A total of 75 subjects (CAD: n ¼ 25; SLE: n ¼ 27; control: n ¼ 23) underwent CMR imaging using a 3-T clinical
scanner. Coronary arteries were visualized by a T2-prepared steady state free precession technique. Coronary wall CE was
visualized using inversion-recovery T1 weighted gradient echo sequence 40 min after administration of 0.2 mmol/kg
gadobutrol. Proximal coronary segments were visually examined for distribution of CE and quantified for contrast-
to-noise ratio (CNR) and total CE area.
RESULTS Coronary CE was prevalent in patients (93%, n ¼ 42) with a diffuse pattern for SLE and a patchy/regional
distribution in CAD patients. Compared with control subjects, CNR values and total CE area in patients with CAD and SLE
were significantly higher (mean CNR: 3.9  2.5 vs. 6.9  2.5 vs. 6.8  2.0, respectively; p < 0.001; total CE area: median
0.8 [interquartile range (IQR): 0.6 to 1.2] vs. 3.2 [IQR: 2.6 to 4.0] vs. 3.3 [IQR: 1.9 to 4.5], respectively; p < 0.001). Both
measures were positively associated with aortic stiffness (CNR: r ¼ 0.61, p < 0.01; total CE area: 0.36, p ¼ 0.03),
hypercholesterolemia (r¼0.68, p<0.001; r¼0.61, p<0.001) and hypertension (r¼0.40, p<0.01; r¼0.32, p<0.05).
CONCLUSIONS We demonstrate that quantification of coronary CE by CNR and total CE area is feasible for detection of
subclinical and clinical uptake of gadolinium within the coronary vessel wall. Coronary vessel wall CE may become an
instrumental novel direct marker of vessel wall injury and remodeling in subpopulations at risk. (J Am Coll Cardiol Img
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ABB R E V I A T I O N S
AND ACRONYMS
CAD = coronary artery disease
CE = contrast enhancement
CMR = cardiac magnetic
resonance
CNR = contrast to noise ratio
CV = cardiovascular
LGE = late gadolinium
enhancement
LV = left ventricle
PWV = pulse wave velocity
SLE = systemic lupus
erythematosus
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763C oronary contrast enhancement (CE) by car-diac magnetic resonance (CMR) is a novel,noninvasive approach for visualization of
gadolinium contrast uptake within the coronary ar-
tery vessel wall. Previous studies demonstrated that
CE colocalizes with mixed and calcified plaques in
advanced coronary artery disease (CAD) (reviewed in
Kuo et al. [1]). We have recently shown that coronary
CE is also present in patients with systemic lupus ery-
thematosus (SLE) despite the absence of cardiovascu-
lar (CV) symptoms (2). Demonstration of subclinical
coronary involvement in subjects with persistent
systemic inflammation, accelerated atherosclerosis,
and increased and premature mortality and
morbidity can be potentially useful for identification
of individuals at risk (3–5).Younger women with SLE
appear to be particularly affected; they experience
an increased rate of coronary events early in the
course of systemic disease (6). As current risk stratifi-SEE PAGE 771cation schemes fail to detect these patients, a nonin-
vasive and radiation-free approach using coronary
CE may help to facilitate identification of early sub-
clinical coronary vessel wall changes in vulnerable
subpopulations (7). Patients with systemic inflamma-
tory diseases, including SLE, are for the first time be-
ing acknowledged as subpopulations with increased
CV risk in practice guidelines (8). Means of early
and noninvasive identification of coronary vascular
changes or strategies for improved prevention in
these patients remain unknown. The aim of the cur-
rent study was to assess the feasibility of coronary
CE to describe differences between patients with
established CAD and SLE, as well as control subjects.
In addition to visualization, we employed 2 methods
of CE quantification: contrast-to-noise ratio (CNR)
and total CE area. We also determined the association
of CE with aortic stiffness, an independent predictor
of increased CV risk.
METHODS
A total of 25 patients with previously known signifi-
cant CAD were included who had evidence of $50%
stenosis on invasive coronary angiography or a pre-
vious myocardial infarction by late gadolinium
enhancement (LGE). Twenty-seven subjects with an
established diagnosis of SLE fulfilling the American
College of Rheumatology revised classification
criteria and with no previous history of cardiac
symptoms were recruited from the Louise Coote
Lupus Unit, St Thomas’ Hospital, London (9). The SLE
disease activity was assessed using the SLE diseaseactivity index score (10). Normotensive sub-
jects (n ¼ 23) with low pre-test likelihood for
CV disease, taking no regular medication,
with evidence of normal coronaries by either
a previous invasive x-ray angiography or
computed tomography (CT) coronary angi-
ography, and consequently, with normal
findings from CMR study, served as control
subjects. A total of 12 SLE subjects and 6
control subjects that had concomitant ac-
quisitions of coronary datasets as well as
pulse wave velocity (PWV) for assessment of
aortic stiffness were included in a previously
published paper (2). Patient characteristics
were recorded for all subjects, including age,
sex, body mass index, renal function, presence of CV
risk factors, and medication. Additional exclusion
criteria were any general contraindication to
contrast-enhanced or adenosine stress CMR. The
study protocol was reviewed and approved by the
local ethics committee, and written informed consent
was obtained from all participants.
All patients underwent CMR for routine assess-
ment of cardiac volumes and function and adenosine
stress myocardial perfusion using a 3-T clinical
scanner equipped with multitransmit technology and
advanced cardiac software package (Achieva, Philips
Healthcare, Best, the Netherlands). LGE imaging was
performed approximately 20 min after an intrave-
nous bolus of 0.2 mmol/kg of body weight of
gadobutrol (Gadovist, Bayer Schering Pharma, Berlin,
Germany) using complete short-axis stack coverage
and long-axis views (2-, 3-, and 4-chamber views)
(11). In-plane flow acquisitions of ascending and
descending aorta and aortic arch were obtained for
PWV measurement during shallow free-breathing,
using a retrospectively gated gradient echo pulse
sequence and signal averaging (for imaging para-
meters please see the Online Appendix) (12).
IMAGE ANALYSIS. All routine CMR analysis was
performed using commercially-available software
following standardized post-processing recommen-
dations (13). Endocardial left ventricle (LV) borders
were manually traced at end-diastole and -systole.
The papillary muscles were included as part of the
LV cavity volume. LV end-diastolic and -systolic vol-
umes were determined using Simpson’s rule. Ejection
fraction was computed as end-diastolic volume – (end-
systolic volume/end-diastolic volume). All volumetric
indexes were normalized to body surface area.
Short-axis LGE images were visually examined for
the presence of regional fibrosis, which showed as
bright areas within the myocardium in 2 fold-over
FIGURE 1 Quantification of Coronary CE
Method 1—contrast to noise ratio (CNR)—is based on measuring signal
intensities (SIs) of the vessel wall and blood pool. Method 2—total contrast
enhancement (CE) area—is used to quantify the total area of enhancement.
Calculation is performed for illustration in a patient with coronary artery
disease. RCA ¼ right coronary artery; ROI ¼ region of interest.
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by exclusion of potential artifacts. Stress and rest
perfusion images were evaluated visually for
the pattern and presence of significant myocardial
ischemia (13). Microvascular disease was established
by circumferential homogeneous gradient of epicar-
dial to endocardial enhancement (13). A space-
averaged PWV was measured between ascending
and thoracic descending aorta using an in-house
developed software, as previously described (14–16).
CORONARY IMAGING TECHNIQUE AND ANALYSIS.
All coronary imaging studies were performed as free
breathing scans with respiratory navigation (details
on sequence parameters are provided in the Online
Appendix). First, coronary arteries were localized by
a 3-dimensional T2-prepared balanced steady-state
free precession CMR angiography sequence (17).
Double-oblique imaging planes parallel to the prox-
imal RCA and LCA were then defined using a 3-point
plan-scan tool for free-breathing targeted volume
CMR angiography with a balanced steady-state free
precession sequence with navigator-gating and
correction (1,2,17). Coronary CE imaging was per-
formed last using a T1-weighted 3-dimensional
gradient echo inversion recovery sequence, typically
40 min after bolus administration, as previouslydescribed (18). Inversion time was determined by a
prior Look-Locker sequence to optimize the contrast
between brightness within the vessel wall due to
gadolinium enhancement and suppressed coronary
blood signal (typical time delay: 190 to 210 ms).
Details of coronary CE post-processing are pro-
vided in the Online Appendix. In brief, 2 observers
(N.V. and R.H.) with high intraobserver and interob-
server reproducibility have analyzed all data in an
independent manner, blinded to the results of inva-
sive or CT angiography as well as to the type of
subject. Datasets were evaluated visually for CE dis-
tribution and severity. CNR was calculated using
measurements of signal intensity in the vessel wall
and blood pool as previously described (Fig. 1, Online
Fig. 1) (1,2). Total CE area was measured by using
nonenhancing parts of coronary vessels as reference
(>2 SD in signal intensity above normal) using
manual delineation of a region of interest (19).
STATISTICAL ANALYSIS. Normality of distributions
was tested with the Kolmogorov-Smirnov statistic.
Categorical data are expressed as percentages,
and continuous variables as mean  SD or median
(interquartile range), as appropriate. Comparison of
independent samples was performed using the Stu-
dent t test, chi-square test, or 1-way analysis of
variance and Kruskal-Wallis (Bonferroni post-hoc and
Fisher exact tests for differences from controls,
respectively), as appropriate for the type of the data.
Intraobserver and interobserver reproducibility and
agreement were performed using Bland-Altman
methods. Associations were explored by simple
linear and binary logistic regression analyses. Cut-off
values for discrimination between health and disease
were derived using receiver-operating characteristic
curve analysis using the point that maximized the
trade-off between specificity and sensitivity. All tests
were 2-tailed, and a p value <0.05 was considered
significant.RESULTS
Patients with CAD were older than SLE patients and
control subjects (p < 0.01) (Table 1). All groups had a
predominance of females. CAD patients also had
more traditional CV risk factors. SLE patients took
disease-modifying agents (steroids [n ¼ 25], myco-
phenolate [n ¼ 17], hydroxychloroquine [n ¼ 11], and
warfarin [n ¼ 12]), whereas both patient groups took
renin-angiotensin system blockers (SLE: n ¼ 14,
52%; CAD: n ¼ 25, 100%), calcium-channel blockers
(SLE: n ¼ 5, 19%; CAD: n ¼ 18, 72%), statins (SLE:
n ¼ 3, 11%; CAD: n ¼ 25, 100%), and aspirin (SLE:
TABLE 1 Patient Characteristics
Control Subjects
(n ¼ 23)
SLE
(n ¼ 27)
CAD
(n ¼ 25) p Value
Age, yrs 44  14 42  16 59  9* <0.01
Female 15 (64) 23 (85)† 16 (64) 0.02
BMI, kg/m2 26  4 24  5 28  6 0.21
Heart rate, beats/min 64  6 61  7 58  9 0.49
Systolic BP, mm Hg 123  12 129  19 139  24* <0.01
Diastolic BP, mm Hg 81  9 85  14 98  16* <0.01
Positive family history of CAD 2 (9) 3 (11) 8 (32)* <0.01
Smoking 3 (13) 5 (20) 10 (4)* <0.01
Hypercholesterolemia 3 (13) 5 (20) 24 (96)* <0.01
Diabetes 0 (0) 0 (0) 5 (23) <0.01
SLEDAI — 0 (0–3) —
History of lupus nephritis — 12 (44) —
Antiphospholipid syndrome — 12 (44) —
eGFR, ml/min 102  7 82  17† 78  19* <0.01
C-reactive protein, mg/l 2.9  1.2 5.1  3.7† 4.9  3.1* 0.04
Erythrocytes sedimentation
rate, mm/h
<7 39  21† —
Values are mean  SD or n (%). One-way analysis of variance and Kruskall-Wallis with post-hoc tests for
differences *for controls vs. coronary artery disease (CAD) patients and †for controls vs. systemic lupus
erythematosus (SLE).
BMI ¼ body mass index; BP¼ blood pressure; CAD ¼ coronary artery disease; ESR¼ erythrocyte sedimentation
rate; eGFR ¼ estimated glomerular filtration rate; SLE ¼ systemic lupus erythematosus; SLEDAI ¼ systemic lupus
erythematosus disease activity index.
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765n ¼ 6, 22%; CAD: n ¼ 25, 100%). SLE patients had low
disease activity, with a median SLE disease activity
index score of 0 (interquartile range: 0 to 3) (Table 1).
Compared with control subjects and SLE patients,
CAD patients had enlarged cardiac volumes, impaired
global systolic function, and increased LV mass
(Table 2). None of the patients had evidence of
significant valvular pathology. Twenty-two CAD pa-
tients had inducible ischemia on adenosine myocar-
dial perfusion testing, whereas 8 patients with SLE
showed a pattern of microvascular disease (Fig. 2).
Eleven SLE patients (41%) showed diffuse peri-
myocardial LGE, most commonly noted in midbasal
inferolateral segments (20). Twenty CAD patients
revealed an ischemic type of LGE (13). PWV was simi-
larly significantly increased in both patient groups.
CORONARY CE ANALYSIS. The proximal course of
both coronary arteries (proximal to mid-segment)
were visualized in all subjects and included in the
visual assessment and quantification analysis of
coronary CE. The image quality was rated as excel-
lent (n ¼ 25), good (n ¼ 42), moderate (n ¼ 7), and
poor (n ¼ 1). The majority of CAD patients (n ¼ 21,
84%) had a previously known severe lesion (>75%
stenosis) in at least 1 of the coronary territories, of
which 11 patients had a total occlusion of the
respective artery. Four control subjects showed mild
coronary CE (Fig. 3A). Coronary CE was prevalent in
both patient groups (Table 2). SLE patients showed
a diffuse enhancement pattern (Fig. 3B), whereas in
patients with CAD, CE was patchy and concentrated
to the areas of minimal lumen diameter (Fig. 3C).
Both patient groups had higher CNR and total CE
area, with no difference between the patient groups.
ANALYSIS OF RELATIONSHIPS. CNR correlated with
PWV and total CE area in the cohort as a whole and
in separate groups (CNR controls: r ¼ 0.51, p < 0.01;
SLE: r ¼ 0.69, p < 0.01; CAD: r ¼ 0.64, p < 0.01)
(Table 3). PWV and CNR were associated with age, but
not with sex. All 3 vascular measures were associated
with hypercholesterolemia and hypertension. Using
binary logistic regression, both CE quantification
measures were able to discriminate between control
subjects and (all) patients (CNR [cut-off: 5.6]: sensi-
tivity 96%, specificity 80%, accuracy 93% [hazard
ratio: 6.1, 95% confidence interval: 2.4 to 10.8,
p < 0.01], area under the curve: 0.95, p < 0.01; total
CE area (cut-off: 1.2 mm2): sensitivity 87%, specificity
72%, accuracy 81% [hazard ratio: 2.9, 95% confidence
interval: 1.3 to 4.4, p ¼ 0.006], area under the curve:
0.82, p < 0.01). For more information about the
reproducibility assessments, please see the Online
Appendix.DISCUSSION
We demonstrate that quantification of coronary CE
by CNR and total CE area provides meaningful values
for discrimination between healthy subjects and
patients with CAD and SLE. We also demonstrate
that quantifiable measures of coronary CE are similar
subclinically in patients with SLE and in patients
with known and clinically-overt CAD, whereas the
distribution of CE pattern is different. Both CE-CNR
and total CE area are associated with PWV and
increased cholesterol, established markers of in-
creased CV risk. Our data suggest that visualization
and quantification of coronary CE may provide a
potential new marker of direct subclinical coronary
remodeling and provide means to identify coronary
involvement in vulnerable subgroups, such as SLE
patients, ahead of symptomatic disease.
The standard approach to CV risk stratification
relies on risk scores that target the benefit of popu-
lation as a whole (8). It is recognized that, in many
relevant subpopulations, CV risk is more compound
and underestimated by these scores (e.g., young
patients with comorbidities—systemic inflammatory
diseases, impaired glucose tolerance, chronic kidney
disease, and so on) (21–23). Imaging strategies of
clinical practice rely on visualization of flow-limiting
stenosis or more recently calcified plaque (invasive
TABLE 2 Volumes and Function by Cardiac Magnetic Resonance
Control Subjects
(n ¼ 23)
SLE
(n ¼ 27)
CAD
(n ¼ 25) p Value
LVED index, ml/m2 79  23 71  18 112  41* <0.001
LVES index, ml/m2 33  11 39  14 68  49* <0.001
Ejection fraction, % 58  7 56  11 46  18* 0.02
LV mass index, g/m2 44  21 49  11 68  31* 0.05
Adenosine perfusion
Abnormal 0 (0) 8 (30) 22 (88) <0.001
Inducible ischemia 0 (0) 0 (0) 19 (76) <0.001
Microvascular disease 0 (0) 8 (30) 0 (0) <0.001
LGE, n present 0 (0) 11 (41)† 20 (80)* <0.01
Pulse wave velocity, m/s 4.7  2.0 8.1  3.1† 8.7  2.6* <0.001
CE intensity 0.002
Mild 4 (17) 3 (11) 2 (8)
Moderate 0 (0) 9 (33) 8 (32)
Severe 0 (0) 15 (66) 15 (60)
CE pattern
Patchy/regional 3 (13) 3 (11)† 19 (76)* <0.001
Generalized 1 (4) 24 (89)† 6 (24)* <0.001
CNR 3.9  2.5 6.9  2.5† 6.8  2.0* <0.001
Total area, mm2 0.8 (0.6–1.2) 3.2 (2.6–4.0)† 3.3 (1.9–4.5)* <0.001
Values are mean  SD, n (%), or median (interquartile range). One-way ANOVA and Kruskall-Wallis with post-hoc
tests for the differences *for controls vs. coronary artery disease (CAD) patients and †for controls vs. systemic
lupus erythematosus (SLE).
CE ¼ coronary enhancement; CNR ¼ contrast to noise ratio; LGE ¼ late gadolinium enhancement; LV ¼ left
ventricular; LVED ¼ left ventricular end-diastolic; LVES ¼ left ventricular end-systolic; other abbreviations as in
Table 1.
FIGURE 2 Representative Images of Myocardial Stress Perfusion De
(A) Inducible ischemia, as evidenced by subendocardial perfusion defect
homogeneous gradient demonstrating epicardial (green arrows) to endo
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766and CT coronary angiography, respectively) or
detection of myocardial ischemia. Even though these
methods provide prognostic information and guide
therapy in symptomatic CV disease (24), their use as
screening tools in young, vulnerable populations is
limited. Repetitive radiation exposure in young pa-
tients is likely not justified despite considerable ef-
forts to reduce radiation dose (25,26). High calcium
score correlates with more aggressive CV disease and
reflects a greater burden in the general population
(27). However, increased calcium score has poor
correlation with disease activity or with the pro-
pensity of atherosclerotic plaques to rupture, making
it difficult to predict acute coronary events (28). A
previous study using calcium imaging in SLE patients
showed that although age and body mass index pre-
dicted increased calcium score, SLE disease activity
was not associated, challenging the utility of calcium
scoring in this particular population (29). Whether
calcium scoring is a useful marker of increased CV
risk in young SLE patients has not been shown.
Several studies reported abnormal myocardial
perfusion in SLE patients; however, perfusion defects
were not regional, as seen in CAD patients, but were
more diffuse as typically seen in microvascular dis-
ease, adding to the pathophysiological distinction
between the 2 conditions (30). Gold-standardfects
in right coronary artery territory (red arrows). (B) Circumferential
cardial (red arrowheads) enhancement.
FIGURE 3 Representative Images of Clinical Findings
(A) Control subject (female, age 38 years) with mild RCA enhancement (blue). (B) A patient with systemic lupus erythematosus (SLE) (female,
age 36 years), generalized coronary enhancement over the projected long-axis view of the RCA. (C) A patient with coronary artery disease
(CAD) (male, age 57 years), with patchy coronary enhancement within the area of soft plaque; short-axis view of the proximal left coronary
artery. LAD ¼ left anterior descending artery; other abbreviations as in Figure 1.
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767methods for assessing coronary wall remodeling
such as intravascular ultrasound or optical coherence
tomography (19) are invasive and unsuitable for
screening of young patients with recognized high
risk.
As a noninvasive imaging strategy that is
radiation-free and acceptable in most subjects, coro-
nary CE imaging thus has the potential to develop
into a novel marker to detect vulnerable individuals
with subclinical coronary involvement. The physio-
logical mechanism of gadolinium tissue uptake is
well documented and corresponds with the extra-
cellular space (31). CE imaging of the myocardium
marks histological substrates such as scar, fibrosis, or
extracellular edema (32,33). Previous studies have
shown that vessel wall CE colocalizes with areas ofmixed and calcified plaque on CT. Coronary CE was
also shown to be associated with acute or chronic
systemic inflammation (1,34). Validation studies
performed in human vascular, mainly carotid, tissue
suggest that gadolinium uptake in coronary vessels
may bear similarities; however, direct histology,
gadolinium quantification, and colocalization in the
coronary vessel wall tissue is not available (35). In
the absence of a direct histological correlate, we as-
sume that findings in SLE patients correspond to
subclinical coronary wall remodeling due to persis-
tent systemic inflammation. A study in patients after
cardiac transplantation lends support in showing
that increased coronary CE corresponds to increased
plaque burden, as demonstrated by intravascular
ultrasound (19). Therefore, it might be possible to
TABLE 3 Results of Bivariate Regression Analyses
CNR Total CE area
r/rho p Value r/rho p Value
CNR 0.43 0.01
Total CE area 0.43 <0.01
Age 0.39 0.01 0.11 0.44
Sex 0.18 0.27 0.16 0.37
Heart rate 0.21 0.21 0.13 0.31
Systolic BP 0.41 <0.01 0.32 0.01
Hypercholesterolemia 0.46 <0.01 0.39 0.01
Hypertension 0.40 <0.01 0.32 0.05
Diabetes 0.29 0.07 0.20 0.19
Pulse wave velocity 0.61 <0.01 0.36 0.03
C-reactive protein 0.38 0.05 0.29 0.09
Ejection fraction 0.31 0.07 0.27 0.11
LV-mass index 0.33 0.05 0.20 0.17
LGE (presence) 0.26 0.12 0.27 0.11
Correlations were performed using Pearson or Spearman tests, as appropriate for the type of the data.
Abbreviations as in Tables 1 and 2.
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768translate these findings to another vulnerable group.
Although several studies have shown the feasibility
of vessel wall CE imaging for the characterization
of atherosclerotic disease (1), uptake of available
gadolinium-based contrast agents is nonspecific
and may represent acute and/or chronic inflamma-
tory elements, such as edema, neovascularization, or
fibrosis.
We demonstrate that coronary CE allows for
discrimination between healthy subjects and patients
with overt CAD and subclinical disease in SLE. We
found that control subjects show relatively little
contrast uptake and lower CNR values, whereas cor-
onary CE is substantial (visually and quantifiably) in
patients with CAD and SLE. The values of CNR and
total CE area in both patient groups are comparable,
despite the differences in age and distribution of the
risk factors and clinical condition. We further show
that CE pattern in SLE is predominantly diffuse,
consistent with accelerated vessel remodeling, con-
trasting the patchy and regional involvement in CAD,
which is more limited to the areas of focal plaque
formation. Thus, qualitative assessment of coronary
CE as present/absent and diffuse/patchy may allow
for rapid discrimination between health/disease and
type of disease, and is potentially of great clinical
utility. Quantification of coronary CE may add a
means to grade severity of disease.
The associations with increased aortic stiffness for
the total cohort as well as for separate groups further
support the concept that coronary CE concords with
adverse vessel wall remodeling and may potentially
provide a new and direct marker for individualizedCV risk assessment in vulnerable subpopulations (21).
Compared with previous studies reporting on coro-
nary CE in patients with systemic inflammatory
diseases (1,34,35), the prevalence of findings is higher
in our study, and several reasons may explain this
observation. Patient selection in the present study
likely contributes most to this difference: patients
with SLE have been recruited from a highly-
specialized rheumatology service for complex sys-
temic inflammatory diseases. It is conceivable that
we included patients with more aggressive systemic
disease, which is also reflected in their coronary
involvement. Patients with CAD were similarly pre-
selected as those with known and significant CAD.
We also employed an optimized sequence with high
spatial resolution at a higher field strength with
greater signal-to-noise ratio (1). A sufficient time delay
between contrast administration and post-contrast
acquisition is crucial for maximized background
tissue and blood suppression by inversion-recovery
pre-pulse to allow for visualization of gadolinium
uptake within the enhanced vessel wall, as previ-
ously reported (between 30 to 45 min after contrast
administration) (18). Finally, we used gadobutrol, a
gadolinium contrast agent with the highest magnetic
“relaxivity,” allowing for the greatest shortening of
T1 relaxation (and contrast) within accumulated tis-
sues (36).
STUDY LIMITATIONS. This was an exploratory and
hypothesis-generating pilot study with a limited
sample size to test the feasibility of coronary CE im-
aging in pre-selected patient populations with a high
CV risk. Thus, a few limitations apply to this study.
We were not able to assess the true interstudy
reproducibility (a repeated study on a different
occasion). In a small number of patients, we repeated
coronary acquisitions within the same study for
various technical reasons; visualization of coronary
CE or quantification measurements was not markedly
different. We specifically focused on the proximal
course of the coronary vessels, which is robust to
visualization by CMR and allows excellent images of
both the left and right coronary systems. Such an
approach likely underlies the high reproducibility of
CNR calculation/area measurement. Stents may pose
an important limitation to future implementation of
coronary CE as they obscure the insight into the
vessel by inducing a void of magnetization, leading
to an underestimation of CE area and obstructing the
CNR calculation. In the present study, however, only
a small number of CAD patients have had stents, and
none of them were within the proximal segments.
This is mainly explained by the nature of their
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769presentation to CMR (upon which they were
recruited to this study) for a test of myocardial
ischemia to guide subsequent coronary intervention.
Because we intend coronary CE as a means to identify
the subclinical coronary injury early in the course of
disease, we believe that it is unlikely that stents
would be present in such patients and they would not
pose a limitation to its use in practice. Associations
with soluble biomarkers of disease and atheroscle-
rotic plaque activity and the correlation with novel
imaging techniques for characterization of athero-
sclerotic coronary plaque composition, such as coro-
nary CT angiography, need to be examined in larger
studies (19,27,35). Finally, the relation with poorer
prognosis and ability to inform and guide the indi-
vidualized risk assessment requires confirmation in
future studies (37).CONCLUSIONS
Taken together, we demonstrate that visualization
and quantification of coronary CE by CNR and total
CE area may provide a new approach to the detection
of subclinical and clinical coronary vessel wall
remodeling and may support new ways to better
characterize patients with SLE. Coronary CE may
provide a potential new marker of individualized
risk assessment in vulnerable subgroups.
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APPENDIX For details on imaging and
sequence parameters, coronary CE post-
processing, and reproducibility assessments,
please see the online version of this article.
